Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study

American Heart Journal

Volumn 135, Issue 4, 1998, Pages

  Van Hout, B A ^a   Bowman, L ^a   Zelinger, D J ^a   Simoons, M L ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; HEALTH CARE COST; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0031970904     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(98)70302-3     Document Type: Article

References (17)

1. EJ Topol RM Califf HF Weisman Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months Lancet 343 1994 881 886
2. PW Serruys P de Jaegere F Kiemeneij A comparison of balloon-expandable–stent implantation with balloon angioplasty in patients with coronary artery disease N Engl J Med 331 1994 489 495
3. The GUSTO Investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 329 1993 673 682
4. F Zijlstra MJ de Boer JCA Hoorntje S Reiffers JHC Reiber H Suryapranata A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction N Engl J Med 328 1993 680 684
5. DB Mark JD Talley EJ Topol Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty Circulation 94 1996 629 635
6. BA Van Hout T van der Woude P de Jaegere Costs and effects of stent implantation versus PTCA: the BENESTENT experience Semin Intervent Cardiol 1 1996 263 268
7. DB Mark MA Hlatky RM Califf Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction N Engl J Med 332 1995 1418 1424
8. MJ De Boer BA van Hout AL Liem H Suryapranata JCA Hoorntje F Zijlstra A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction Am J Cardiol 76 1995 830 833
9. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty N Engl J Med 330 1994 956 961
10. 3 blockade with percutaneous coronary intervention JAMA 278 1997 479 484
11. L Bonneux JJ Barendregt K Meeter GJ Bonsel PJ van der Maas Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure Am J Public Health 84 1994 20 28
12. The CAPTURE Investigators Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study Lancet 349 1997 1429 1435
13. The EPILOG Investigators Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization N Engl J Med 336 1997 1689 1696
14. BA Van Hout M Al GS Gordon FFH Rutten Costs, effects and C/E-ratios alongside a clinical trial Health Econ 3 1994 309 319
15. BA Van Hout ML Simoons Costs and effects of c7E3 in high risk PTCA patients: an indirect analysis for The Netherlands Eur Heart J 16 Suppl L 1995 81 85
16. E Elsinga FFH Rutten Economic evaluation in support of national health policy: the case of The Netherlands Soc Sci Med 45 1997 605 620
17. BC Michel MJ Al WJ Remme Economic aspects of treatment with captopril for patients with asymptomatic left ventricular dysfunction in The Netherlands Eur Heart J 17 1996 731 740